Who are venlafaxine XR plus aripiprazole's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/venlafaxine-xr-plus-aripiprazole.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

venlafaxine XR plus aripiprazole — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

venlafaxine XR plus aripiprazole (venlafaxine XR plus aripiprazole) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SNRI plus atypical antipsychotic combination. Area: Psychiatry / Mental Health.

marketed SNRI plus atypical antipsychotic combination Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine D2 receptor Psychiatry / Mental Health Small molecule Live · refreshed every 30 min

Target snapshot

venlafaxine XR plus aripiprazole (venlafaxine XR plus aripiprazole) — University of Pittsburgh. Venlafaxine XR inhibits serotonin and norepinephrine reuptake while aripiprazole acts as a dopamine D2 receptor partial agonist, together addressing both depressive and psychotic symptoms.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
venlafaxine XR plus aripiprazole TARGET	venlafaxine XR plus aripiprazole	University of Pittsburgh	marketed	SNRI plus atypical antipsychotic combination	Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine D2 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SNRI plus atypical antipsychotic combination class)

University of Pittsburgh · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). venlafaxine XR plus aripiprazole — Competitive Intelligence Brief. https://druglandscape.com/ci/venlafaxine-xr-plus-aripiprazole. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab